Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C, Chronic

Explore clinical trials studying Hepatitis C, Chronic. Study availability and eligibility vary by location and protocol.

314 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C, Chronic trial results

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • La Jolla, California, United States
  • Long Beach, California, United States
  • San Diego, California, United States
  • San Diego, California, United States
View all 25 locations
View Trial Details
Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

NCT01528735

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.25.002 Boehringer Ingelheim Investigational Site Kofu, Yamanashi, Japan
  • 1241.25.005 Boehringer Ingelheim Investigational Site Kurashiki, Okayama, Japan
  • 1241.25.003 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan
  • 1241.25.004 Boehringer Ingelheim Investigational Site Nishinomiya, Hyogo, Japan
View Trial Details
Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.

NCT00087594

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • San Francisco, California, United States
  • Farmington, Connecticut, United States
  • Honolulu, Hawaii, United States
  • Downers Grove, Illinois, United States
View Trial Details
Completed

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Anchorage, Alaska, United States
  • Phoenix, Arizona, United States
View all 132 locations
View Trial Details
Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.36.00016 Boehringer Ingelheim Investigational Site North Little Rock, Arkansas, United States
  • 1241.36.00020 Boehringer Ingelheim Investigational Site Anaheim, California, United States
  • 1241.36.00005 Boehringer Ingelheim Investigational Site Bakersfield, California, United States
  • 1241.36.00009 Boehringer Ingelheim Investigational Site La Jolla, California, United States
View all 109 locations
View Trial Details

Related conditions